Poloxamer-188 Adjuvant Efficiently Maintains Adaptive Immunity of SARS-CoV-2 RBD Subunit Vaccination through Repressing p38MAPK Signaling

Poloxamer-188 Adjuvant Efficiently Maintains Adaptive Immunity of SARS-CoV-2 RBD Subunit Vaccination through Repressing p38MAPK Signaling

Year2022
Author柯冠銘*
Author count1
Created date2022-09-24
Author order第一作者
Corresponding author
Publication year2022
Publication month5
Journal nameVaccines (Basel)
Publication area瑞士聯邦
Volume10
Issue5
Publication type
Review system
LanguageForeign Language